New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Merck & Co., Inc.

MRK

Healthcare Drug Manufacturers General

Merck & Co., Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.0 billion, up 1.31% from fiscal 2024.

Revenue
+4.68%
EPS
−12.1%
Free cash flow
−19.3%
Total debt
+24.3%

Quarter to September 2026, against a year earlier

134.95 2.21 +1.66%
Market cap
$328.6B
P/E
137×
Fwd P/E FY26e
105×
Dividend yield
2.56%
F-score
4/9
ROIC
4.56%
Net debt / EBITDA
1.2×
Payout ratio
3.5×

Where the cash went Q3 FY2026, quarter to Sep 30, 2026

Free cash flow of $5.5B covered $2.5B of dividends and buybacks. Cash rose by $2.8B. What is a cash flow statement?

Free cash flow
$5.5B 84.1% of operating cash flow
Returned to shareholders
$2.5B 45.4% of free cash flow
Debt, net
$0.00 borrowed
Change in cash
+$2.8B over the period
Where the cash went, in billions of dollars
Operating cash flow6.6
Capital expenditures−1.0
Free cash flow5.5
Acquisitions, net−0.6
From investments, net+0.4
Dividends−2.1
Buybacks, net−0.4
Other0.0
Change in cash2.8
Operating cash flowCapexFree cash flow
Operating cash flow, capex and free cash flow, four quarters
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Operating cash flow$2.9B$3.9B$5.4B$6.6B
Capex−$1.0B−$991M−$893M−$1.0B
Free cash flow$1.8B$2.9B$4.5B$5.5B

Figures in billions of dollars. Free cash flow is operating cash flow less capital expenditures. Investments are purchases less sales of securities; “Other” is what the named lines leave of the change in cash.

Sep '26 Jun '26 Mar '26 Dec '25 Older periods
Net Income
5,067.00 (1,337.00) (4,243.00) 2,962.00

+8 more quarters

Operating Cash Flow
6,558.00 5,370.00 3,918.00 2,857.00
Investing cash flow
(1,319.00) (5,602.00) (10,210.00) (11,201.00)
Financing cash flow
(2,432.00) 1,762.00 (2,981.00) 4,751.00
Ending Cash
2,761.00 1,493.00 5,398.00 (3,570.00)

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026